TIDMOBD
Oxford BioDynamics PLC
28 October 2020
Oxford BioDynamics Plc
Oxford BioDynamics advances EpiSwitch(TM) disease severity
program for COVID-19 with top US academic health center, Oregon
Health & Science University
-- Expertly annotated patient samples from world-class clinical research facility
-- Samples used to advance development of the world's first 3D
genomic severity test for COVID-19 disease built using the
EpiSwitch(TM) platform
-- Goal is to provide insight into a wide range of COVID-19 responses, from mild to severe
-- Adds to Oxford BioDynamics' growing bank of 500+ procured
samples from cohorts around the world
Oxford, UK- 28 October 2020 - Oxford BioDynamics Plc (AIM: OBD),
a biotechnology company developing personalized medicine tests
based on 3D genomic biomarkers, has signed a Human Material and
Data Transfer Agreement with Oregon Health & Science University
(OHSU) as part of its EpiSwitch(TM) COVID-19 disease severity test
program.
Some people infected with COVID-19 become severely ill and
hospitalized, while many only experience mild illness. Under the
terms of the agreement, samples from OHSU will be used to further
the development of the Company's COVID-19 severity test, aimed at
forecasting individuals' risks of severe disease progression in
advance, to inform risk mitigation decisions and help optimize
acute and long-term treatment.
Ranked among the best hospitals in the US,(1) OHSU has been
operating right at the frontline throughout the pandemic. Since 28
February, with the first US COVID-19 hotspot on its doorstep, OHSU
has seen 3,950 patient cases, as of 26 October.(2) Clinicians have
encountered and treated patients experiencing a wide range of
responses, from asymptomatic through to severe cases who were
admitted to intensive care or succumbed.
OHSU is the first US Academic Medical Centre to join Oxford
BioDynamics' disease severity program on a non-commercial basis as
part of the COVID-19 Technology Access Framework initiative it is
involved with. (3) OHSU is providing clinical research samples from
patients with the full spectrum of manifestations of COVID-19,
together with in-depth expert description and annotation . These
add to Oxford BioDynamics' growing bank of 500+ samples from
cohorts across the world. The Company is developing the world's
first 3D genomic test to determine likelihood of disease severity
(prognostic).
Dr Jon Burrows, CEO of Oxford BioDynamics commented: "We are
gratified that our disease severity program has attracted the
attention and support of a prestigious institution like OHSU. The
well-annotated samples provided by this world-class facility will
deepen our understanding of patient response and enhance
development of our test. We are continuing to grow our network of
leading international institutions interested in analysing how the
3D genome informs COVID-19 response."
Oxford BioDynamics is developing the disease severity test based
on its proprietary EpiSwitch(TM) technology which has been reduced
to practice.(4) EpiSwitch(TM) will be used to retrospectively
analyse the OHSU samples, comparing the 3D genomes of the patients
to how they responded to the virus. The 3D structure of a patient's
genome contains important molecular regulatory information, about
what makes certain patients particularly vulnerable to
hyperinflammation and severe side effects, when exposed to COVID-19
infection. Oxford BioDynamics is establishing a panel of biomarkers
to forecast the expected severity when infected with COVID-19. This
will help to assess an individual's level of risk and assist in
patient prognoses. Having this information could significantly help
patient triage and treatment, ease the burden on healthcare systems
and human resources.
Bill Messer, MD, PhD, Assistant Professor of Molecular
Microbiology and Immunology, School of Medicine, OHSU added : "With
the second wave of COVID-19 sweeping the globe, it is clear that we
have a way to go in the fight against this virus. In April, we
joined the COVID-19 Technology Access Framework, which aims to
expedite the development of promising technologies to diagnose,
treat and prevent COVID-19. Oxford BioDynamics shares the same
mission, and their technology and its prognostic capabilities hold
potential in helping both patients and the health care system. We
are glad to contribute our samples and knowledge to help advance
development of the Company's COVID-19 disease severity test."
References:
1.
https://www.ohsu.edu/health/ohsu-health-care-awards-and-recognition
2.
https://news.ohsu.edu/2020/10/19/preparing-for-the-novel-coronavirus-at-ohsu
3.
https://news.ohsu.edu/2020/04/16/ohsu-expedites-promising-new-technologies-to-tackle-covid-19
4.
https://www.oxfordbiodynamics.com/wp-content/uploads/2020/06/SITC2019_P142_avelumab.pdf
- ENDS -
FOR MORE INFORMATION:
Oxford BioDynamics Plc Instinctif Partners
Jon Burrows, CEO Melanie Toyne-Sewell
Alexandre Akoulitchev, CSO Agnes Stephens
Paul Stockdale, CFO Katie Duffell
E: enquiries@oxfordbiodynamics.com T: +44 (0) 20 7457 2013
E: oxfordbiodynamics@instinctif.com
NOTES TO EDITORS:
About Oxford BioDynamics Plc
Oxford BioDynamics Plc (AIM: OBD) ("Oxford BioDynamics") is a
biotechnology company focused on the discovery and development of
3D genomic biomarkers for use within the pharmaceutical and
biotechnology industry.
The Company's award-winning, proprietary technology platform,
EpiSwitch(TM), aims to accelerate the drug discovery and
development process, improve the success rate of therapeutic
product development and take advantage of the increasing importance
of personalised medicine.
In particular, EpiSwitch(TM) can reduce time to market, failure
rates and the costs at every stage of drug discovery. Additionally,
the technology provides significant insights into disease
mechanisms for drug discovery and product re-positioning programs,
enabling the personalization of therapeutics for patients in the
context of challenging pricing environments where improved clinical
outcomes are critical.
In April 2019, Oxford BioDynamics received the Queen's Award for
Enterprise: Innovation. The Queen's Awards for Enterprise are the
most prestigious awards for UK businesses.
The Company is headquartered in the UK and listed on the London
Stock Exchange's AIM under the ticker "OBD". For more information
please visit our website, www.oxfordbiodynamics.com , or follow us
on Twitter or LinkedIn .
This information is provided by Reach, the non-regulatory press
release distribution service of RNS, part of the London Stock
Exchange. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
NRAFLFEDILLDFII
(END) Dow Jones Newswires
October 28, 2020 03:00 ET (07:00 GMT)
Oxford Biodynamics (LSE:OBD)
Historical Stock Chart
From Apr 2024 to May 2024
Oxford Biodynamics (LSE:OBD)
Historical Stock Chart
From May 2023 to May 2024